EP. 1: Understanding VMS in Menopause: Prevalence and Impact
March 28th 2025Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.
EP. 2: Beyond Hormone Therapy: Effective Alternatives for Managing Menopausal Symptoms
March 28th 2025Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.
EP. 5: Liver Safety and Monitoring in VMS Treatment
March 28th 2025Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.
EP. 8: Educating Patients and Providers: Key Takeaways for Better VMS Management
March 28th 2025Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.